Dynamic history of low‐grade gliomas before and after temozolomide treatment

To evaluate the natural progression and the impact of temozolomide in low‐grade gliomas and to correlate these changes with the profile of genetic alterations.

[1]  N. Probst-Hensch,et al.  Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas , 2004, Acta Neuropathologica.

[2]  L. Donehower,et al.  Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas , 1995, Molecular and cellular biology.

[3]  K. Hoang-Xuan,et al.  Chromosome 1p loss: A favorable prognostic factor in low‐grade gliomas , 2005, Annals of neurology.

[4]  Takaaki Kirino,et al.  Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  Allan H Friedman,et al.  Phase II trial of temozolomide in patients with progressive low-grade glioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Ashley,et al.  Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Laurent Capelle,et al.  Continuous growth of mean tumor diameter in a subset of grade II gliomas , 2003, Annals of neurology.

[8]  K. Hoang-Xuan,et al.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Cianciulli,et al.  Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Murray,et al.  Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion , 2003, Journal of the Neurological Sciences.